

### Technical Manual

# pGL2 Luciferase Reporter Vectors

INSTRUCTIONS FOR USE OF PRODUCTS E1611, E1621, E1631 AND E1641.





## pGL2 Luciferase Reporter Vectors

All technical literature is available on the Internet at: www.promega.com/tbs/
Please visit the web site to verify that you are using the most current version of this
Technical Bulletin. Please contact Promega Technical Services if you have questions on use
of this system. E-mail: techserv@promega.com

I.	Description	1
II.	Product Components and Storage Conditions	2
	A. Structure and Function B. pGL3 and pGL4 Vectors	2
IV.	pGL2 Vector Maps and Multiple Cloning Region  A. pGL2-Basic Vector  B. pGL2-Promoter Vector  C. pGL2-Enhancer Vector  D. pGL2-Control Vector	4 5
V.	Vector Manipulation	8 9
VI.	Transfection of Eukaryotic Cells	10
VII.	Assays of Luciferase Activity	11
VIII.	Appendix  A. pGL2-Basic Vector Restriction Sites.  B. pGL2-Promoter Vector Restriction Sites  C. pGL2-Enhancer Vector Restriction Sites  D. pGL2-Control Vector Restriction Sites  E. References	13 15 18
	F Related Products	22

#### I. Description

The pGL2 Luciferase Reporter Vectors<sup>(a)</sup> are designed for the quantitative analysis of factors that potentially regulate mammalian gene expression. These factors may be cis-acting, such as promoters and enhancers, or trans-acting, such as various DNA-binding factors. The pGL2 Vectors carry the coding region for wildtype firefly (*Photinus pyralis*) luciferase, used to monitor transcriptional activity in transfected eukaryotic cells. The assay of this genetic reporter is rapid, sensitive and quantitative. In addition, the pGL2 Vectors contain numerous features that aid the characterization and mutagenesis of the putative regulatory sequences.



#### II. Product Components and Storage Conditions

Product	Size	Cat.#
pGL2-Control Vector	20μg	E1611
pGL2-Enhancer Vector	20μg	E1621
pGL2-Promoter Vector	20μg	E1631
pGL2-Basic Vector	20μg	E1641

Vectors are supplied with a glycerol stock of bacterial strain JM109. Information on related products, including the Luciferase Assay System, is provided in Section VII.

**Storage Conditions:** Store the vector DNA at  $-20^{\circ}$ C. Store the JM109 cells at  $-70^{\circ}$ C

#### III. General Considerations

#### III.A. Structure and Function

Promega supplies four different pGL2 Vectors: pGL2-Basic, pGL2-Promoter, pGL2-Enhancer and pGL2-Control. Each vector carries the luciferase gene (luc) followed by the SV40 small t antigen intron and early polyadenylation [poly(A)] signals. A second copy of the poly(A) site, located upstream of the luciferase coding region, limits background transcription from spurious promoters in the plasmids. The vectors also contain a high copy number prokaryotic origin of replication for maintenance in E. coli, an ampicillinresistance gene for selection and a filamentous phage origin of replication (f1 ori) for single-stranded DNA (ssDNA) production. Restriction sites for insertion of DNA fragments are located upstream and downstream of the luciferase gene. Two of the upstream sites (XhoI and BglII) yield cohesive ends compatible with the downstream sites (SalI and BamHI, respectively), allowing the interchange of the DNA insert for rapid analysis of positional effects. Except for the inclusion of promoters and enhancers, the four pGL2 Vectors are structurally identical. Specific features of each plasmid are summarized in Section IV. Maps of the pGL2-Basic, pGL2-Promoter, pGL2-Enhancer and pGL2-Control Vectors are shown in Figures 1-5. The list of restriction sites for these vectors is provided in Section VIII.



#### III.B. pGL3 and pGL4 Vectors

Promega also provides two improved series of luciferase reporter vectors, the pGL3 Luciferase Reporter Vectors and pGL4 Luciferase Reporter Vectors. The pGL3 family of Luciferase Reporter Vectors provides significant advances over the pGL2 family (1). The pGL3 Reporter Vectors contain a modified firefly luciferase cDNA, designated *luc+*, and a redesigned vector backbone. These changes were made to increase luciferase expression, improve in vivo vector stability, and provide greater flexibility in performing genetic manipulations. The modified reporter vectors have resulted in luciferase expression levels dramatically higher than those obtained with the pGL2 Reporter Vectors, while maintaining relatively low background luciferase expression. For further information, please request the *pGL3 Luciferase Reporter Vectors Technical Manual #TM033*.

The pGL4 Luciferase Reporter Vectors are the latest generation of reporter gene vectors optimized for expression in mammalian cells. Numerous configurations of pGL4 Vectors are available, including those with the synthetic firefly luc2 (Photinus pyralis) and Renilla hRluc (Renilla reniformis) genes, which have been codon optimized for more efficient expression in mammalian cells. Furthermore, both the reporter genes and the vector backbone, including the bla ( $\beta$ -lactamase or Amp¹) and mammalian selectable marker genes for hygromycin (Hygro or Hyg¹), neomycin (Neo or Neo¹) and puromycin (Puro or Puro¹), have been engineered to reduce the number of consensus transcription factor binding sites, reducing background and the risk of anomalous transcription. For more information, see the pGL4 Luciferase Reporter Vectors Technical Manual #TM259 available at: www.promega.com/tbs/



#### IV. pGL2 Vector Maps and Multiple Cloning Region

#### IV.A. pGL2 Basic Vector

The pGL2-Basic Vector lacks eukaryotic promoter and enhancer sequences, allowing maximum flexibility in cloning putative regulatory sequences. Expression of luciferase activity in cells transfected with this plasmid depends on insertion and proper orientation of a functional promoter upstream from *luc*. Potential enhancer elements can also be inserted upstream of the promoter or in the BamHI or SalI sites downstream of the luciferase gene.




Figure 1. pGL2-Basic Vector map.

/ \
(none)
(none)
1-53
77-99
76-1728
2518-2739
2796-2815
3815-4675
3053
4807-5262
5565-5587



#### IV.B. pGL2-Promoter Vector

The pGL2-Promoter Vector contains the SV40 promoter upstream of the luciferase gene. DNA fragments containing putative enhancer elements can be inserted in either orientation and upstream or downstream of the promoter-*luc* transcriptional unit.




Figure 2. pGL2-Promoter Vector map.

Multiple cloning region	1-49
SV40 Promoter	42-244
Luciferase gene ( <i>luc</i> )	268-1920
GLprimer2 binding site	269-291
RVprimer4 binding site	2988-3007
ColE1-derived plasmid replication origin	3245
β-lactamase (Amp <sup>r</sup> ) gene	4007-4867
f1 origin	4999-5454
GLprimer1 binding site	5757-5779



#### IV.C.pGL2-Enhancer Vector

The pGL2-Enhancer Vector contains an SV40 enhancer, derived from the SV40 early promoter, located downstream of the luciferase gene after the poly(A) signal. This aids in the verification of functional promoter elements because the presence of the enhancer in many cases will result in transcription of *luc* at higher levels.




Figure 3. pGL2-Enhancer Vector map.

Multiple cloning region	1-52
Luciferase gene (luc)	76-1728
GLprimer2 binding site	77-99
SV40 late poly(A) signal	2518-2739
SV40 Enhancer	2748-2984
RVprimer4 binding site	3053-3072
ColE1-derived plasmid replication origin	3310
β-lactamase (Amp <sup>r</sup> ) gene	4072-4932
f1 origin	5064-5519
GLprimer1 binding site	5822-5844



#### IV.D. pGL2-Control Vector

The pGL2-Control Vector contains the SV40 promoter and enhancer sequences, resulting in strong *luc* expression in many types of mammalian cells. This plasmid is useful in monitoring transfection efficiency in general and is a convenient internal standard for promoter and enhancer activities expressed by pGL2 recombinants.





Figure 4. pGL2-Control Vector map.

SV40 Promoter	42-244
Luciferase gene (luc)	268-1920
GLprimer2 binding site	269-291
SV40 late poly(A) signal	2710-2931
SV40 Enhancer	2940-3176
RVprimer4 binding site	3245-3264
ColE1-derived plasmid replication origin	3502
β-lactamase (Amp <sup>r</sup> ) gene	4264-5124
f1 origin	5256-5711
GLprimer1 binding site	6014-6036



#### IV.D. pGL2-Control Vector (continued)



**Figure 5.** pGL2 Vector multiple cloning region. Shown are the upstream and downstream cloning regions and the locations of the sequencing primers, GLprimer1 and GLprimer2. The arrows for the primers indicate the direction of sequencing. The positions of the promoter (in the pGL2-Promoter and pGL2-Control Vectors) and the enhancer (in the pGL2-Enhancer and pGL2-Control Vectors) are shown as insertions into the sequence of the pGL2-Basic Vector. (Note that the promoter replaces four bases of the pGL2-Basic Vector.) The sequence shown is of the DNA strand synthesized by the f1 ori.

#### V. Vector Manipulation

#### V.A. Cloning Strategies

For most applications, we recommend cloning into the XhoI or BgIII sites upstream of *luc* or the SalI and BamHI sites downstream. XhoI and SalI have compatible ends, as do BgIII and BamHI, which allow easy interchange of inserts between upstream and downstream positions relative to the luciferase gene. Thus, positional effects of a putative genetic element may be readily tested. Cloning fragments into a single site will generally yield both possible orientations relative to the reporter gene, making these effects also readily testable.

The other upstream restriction sites may be used for cloning; however, note that some of the sites are required for generation of nested deletions (see Section V.B). Specifically, the KpnI or SacI site is needed to generate a 3′-overhang, and the MluI, NheI or XhoI site is needed to generate a 5′-overhang. The HindIII site may be used for cloning, but it should be noted that this site occurs downstream of the promoter in the pGL2-Promoter and pGL2-Control Vectors.

PromegaCorporation· 2800WoodsHollowRoad· Madison,WI53711-5399USAToll Free in USA800-356-9526· Phone608-274-4330· Fax608-277-2516· www.promega.comPart# TM003<br/>Page 8Printed in USA.<br/>Revised 3/07



The SmaI/XmaI site upstream of the restriction sites mentioned above can be used to insert other putative regulatory elements without compromising the ability to make nested deletions. It can also be used to aid in mapping nested deletions.

Because the pGL2 Vectors are supplied as modified DNA, *E. coli* hosts may be either restriction+ or restriction–. The pGL2 Vectors are supplied with JM109 (endA1, recA1, gyrA96, thi, hsdR17, ( $r_K$ -, $m_K$ +), relA1, supE44,  $\Delta$ (lac-proAB), [F´, traD36, proAB, lacIqZ $\Delta$ M15]). The use of a recA host such as JM109 is preferred because this prevents undesirable recombination between the insert and the host chromosomal DNA. A strain that has an F´ episome is required for ssDNA production. Grow JM109 on minimal plates (M-9) supplemented with thiamine-HCl prior to preparation of competent cells and transformation. This selects for the presence of the F´ episome.

Protocols for restriction digestion, alkaline phosphatase treatment, linker ligation and transformation of competent cells can be found in our *Protocols and Applications Guide, Third Edition* or in reference 2.

#### V.B. Mapping Genetic Elements Located within DNA Fragments

The locations of functional elements within a DNA fragment are often determined by making a set of unidirectional deletions following the method of Henikoff (3) and assaying for biological activity. This method takes advantage of the unique properties of Exonuclease III (ExoIII), which will digest 5'-overhangs, but not 3'-overhangs or α-phosphorothioate nucleotide filled-in overhangs. Nested deletions of the insert can be made directly in the promoter regions of the pGL2-Promoter and pGL2-Control Luciferase Reporter Vectors using this method, eliminating the need for subcloning steps. The upstream MluI, NheI and XhoI sites, rare restriction sites in eukaryotic DNA, provide the potential 5´-starting points for ExoIII digestion at the upstream end of the insert; KpnI and SacI generate the 3'-overhangs resistant to ExoIII. After treatment with ExoIII, S1 nuclease is added to remove the resulting ssDNA, and T4 DNA ligase is added to reclose the vectors. Deletion clones can be screened by gel electrophoresis of miniprep DNA, and the precise deletion endpoints within the promoter region can be determined by DNA sequencing using primers designed for the pGL2 Vectors.



#### V.C. Sequencing

For some applications, it may be desirable to sequence the DNA inserted into the pGL2 Vectors. Two examples of such applications are to determine the exact position of generated deletions (see Section V.B) and to confirm production of a site-specific mutation. Two primers are available for this purpose: GLprimer1 for sequencing clockwise across the upstream cloning sites, and GLprimer2 for sequencing counterclockwise across the cloning sites.

GLprimer1 5′-TGTATCTTATGGTACTGTAACTG-3′
GLprimer2 5′-CTTTATGTTTTTGGCGTCTTCCA-3′

GLprimer1 is especially useful for identifying positions of nested deletions. Note that both primers can be used for dsDNA sequencing, but GLprimer2 also may be used for ssDNA sequencing.

#### VI. Transfection of Eukaryotic Cells

Transfection of DNA into eukaryotic cells may be mediated by cationic lipid compounds (4,5), calcium phosphate (6,7), DEAE-dextran (6,8), or electroporation (7). Transfection systems based on cationic lipids (TransFast<sup>TM</sup> Transfection Reagent, Transfectam® Reagent and Tfx<sup>TM</sup> Reagents), calcium phosphate and DEAE-dextran (Profection® Mammalian Transfection Systems) are available from Promega. For more information on these transfection reagents, please request the *TransFast*<sup>TM</sup> *Transfection Reagent Technical Bulletin* #TB260, the *Transfectam® Reagent Technical Bulletin* #TB116, the *Tfx*<sup>TM</sup>-*Reagents Technical Bulletin* #TB216 or the *ProFection® Mammalian Transfection Systems Technical Manual* #TM012. All of these documents are available on our web site at: www.promega.com/tbs/

**Note:** The specific transcriptional characteristics of the pGL2 Vectors are likely to vary for different cell types. This may be particularly true for COS cells that contain the SV40 large T antigen. The SV40 large T antigen promotes replication of the SV40 origin, found in the promoter region of the pGL2-Promoter and pGL2-Control Vectors. The combination of large T antigen and SV40 origin will result in a higher copy number of these vectors in COS cells, which in turn may result in increased expression of the reporter gene compared to expression levels from vectors lacking the SV40 origin.



#### VII. Assays of Luciferase Activity

Experimental strategies using firefly luciferase may involve the analysis of a few samples per day or as many as several thousand samples per hour, and equipment used to measure luminescence may vary from inexpensive, single-sample luminometers to high-end CCD luminometers. To support this wide range of applications, Promega has developed three luciferase assays with different but complementary characteristics: Luciferase Assay System (Cat.# E1500), Bright-Glo<sup>TM</sup> Luciferase Assay System (Cat.# E2610), and Steady-Glo<sup>®</sup> Luciferase Assay System (Cat.# E2510). Reagent choice depends on the relative importance of experimental format, assay sensitivity and luminescence duration.

Table 1. Characteristics of Promega Luciferase Assay Reagents.

			Luciferase
	Bright-Glo™	Steady-Glo®	Assay
	Reagent	Reagent	Reagent
Format	NH or H	NH or H	NH
Process	continuous	batch	bench scale
Number of Steps	1	1	4
Sensitivity	highest	lower	higher
Signal Half-Life	~30 minutes	~5 hours	~12 minutes
Precision	High	High	High
Cell Lysis Time	~2 minutes	~5 minutes	NA

NH = nonhomogeneous (first create a lysate); H = homogeneous; NA = not applicable

The Luciferase Assay System has long been the standard reagent for routine laboratory analysis. Before using this reagent, cells from which the luciferase is to be measured must be washed and lysed. This reagent was optimized for high sensitivity in nonhomogeneous, single-sample measurements. The Luciferase Assay System requires a luminometer fitted with injectors to efficiently measure luminescence in 96-well plates.

The Bright-Glo™ and Steady-Glo® Reagents were developed to perform assay reactions within multiwell plates and in the presence of complete cell culture medium: no cell preparation steps such as washing or lysing are required before the luminescence reaction is initiated. Both of these are single-step reagents, requiring only addition of the reagent before measuring luminescence. This makes them ideal reagents for efficient and precise quantitation in 96-, 384- and 1536-well plates.



The Bright-Glo™ and Steady-Glo® Reagents are complementary in their characteristics based on the inverse relationship between luminescence duration and assay sensitivity (9). Generally as the half-life of the luminescence increases, assay sensitivity decreases. The Steady-Glo® Reagent provides long luminescence duration (changing only about 10% per hour); however, to achieve this long luminescence duration, the assay sensitivity must be reduced. This reagent was designed for experiments in which many microplates are processed as a batch.

In contrast, the Bright-Glo™ Reagent provides high assay sensitivity with shorter luminescence duration (<10% decrease per 5 minutes). This reagent is designed for general research applications and for experiments using robotics for continuous sample processing. Furthermore, as a result of increased sample capacity, the Bright-Glo™ Reagent provides greater assay sensitivity than the Luciferase Assay Reagent in most applications (9).

The Luciferase Assay System, Bright-Glo™ Reagent and Steady-Glo® Reagent provide the highest standards in assay quantitation, sensitivity and convenience. Since these reagents are based on the same underlying design principles, different reagents can be used as experimental needs change. For more information request the Luciferase Assay System Technical Bulletin #TB281, the Steady-Glo® Luciferase Assay System Technical Manual #TM051, or the Bright-Glo™ Luciferase Assay System Technical Manual #TM052.

When studying promoter functionalities, it is often desirable to include a second reporter (e.g., *Renilla* luciferase) as an internal control for normalization. Plasmids derived from pGL2, pGL3 or pGL4 vectors can be co-transfected with *Renilla* luciferase vectors, such as phRL-TK, and assayed using the Dual-Luciferase® Reporter Assay System (Cat.# E1910) or the Dual-Glo<sup>TM</sup> Luciferase Assay System (Cat.# E2920).

Table 2. Characteristics of Promega Dual-Luciferase Assays.

	Dual-Luciferase®	Dual-Glo™
	Assay	Assay
Format	NH	Н
Process	bench scale	batch
Number of Steps	5	2
Sensitivity	higher	lower
Signal Half-Life – firefly	~9 minutes	~2 hours
Signal Half-Life – Renilla	~2 minutes	~2 hours
Precision	High	High
Cell Lysis Time	~10 minutes	~15 minutes

NH = nonhomogeneous (first create a lysate); H = homogeneous



#### VIII. Appendix

#### VIII.A. pGL2-Basic Vector Restriction Sites

The following restriction enzyme tables were constructed using DNASTAR® sequence analysis software. Please note that we have not verified this information by restriction digestion with each enzyme listed. The location given specifies the 3′ end of the cut DNA (the base to the left of the cut site). For more information on the cut sites of these enzymes, or if you identify a discrepancy, please contact your local Promega Branch or Distributor. In the U.S., contact Promega Technical Services at 800-356-9526. The pGL2-Basic Vector sequence is also available in the GenBank® database (GenBank®/EMBL Accession Number X65323) and online at: www.promega.com/vectors/

Table 3. Restriction Enzymes That Cut the pGL2-Basic Vector 1-5 Times.

Enzyme	# of Sites	Location	Enzyme	# of Sites	Location
AccB7I	1	2044	BssSI	2	3168, 4552
AccI	1	2746	BstEII	1	683
AccIII	2	771, 1287	Bsu36I	1	689
Acc65I	1	8	Cfr10I	5	345, 1504, 2863,
AcyI	4	83, 109, 1502,			3968, 4932
		4425	ClaI	1	1441
AflIII	3	22, 569, 2995	Csp45I	2	245, 1033
Alw26I	4	1099, 1331, 3949,	DraII	1	1255
		4725	DraIII	1	5040
Alw44I	2	3309, 4555	DrdI	2	3103, 5084
AlwNI	1	3411	EaeI	1	4276
AspHI	5	18, 1541, 3313,	<b>EclHKI</b>	1	3888
_		4474, 4559	Eco47III	1	2871
AvaI	3	1, 33, 1132	Eco81I	1	689
AvaII	3	1255, 4026, 4248	<b>EcoICRI</b>	1	16
BamHI	1	2739	EcoNI	1	1693
BanII	3	18, 1100, 4966	<b>EcoRI</b>	1	663
BbeI	1	112	<b>EcoRV</b>	1	1414
BbsI	5	86, 1364, 1480,	EheI	1	110
		2192, 2824	FspI	2	4110, 5283
BbuI	1	739	HaeII	5	112, 2873, 3243,
BglI	2	4008, 5276			4882, 4890
BglII	1	37	HincII	4	1380, 2608, 2747,
BsaI	1	3949			5451
BsaAI	3	230, 5037, 5370	HindII	4	1380, 2608, 2747,
BsaBI	1	2507			5451
BsaHI	4	83, 109, 1502,	HindIII	1	47
		4425	HpaI	2	2608, 5451
BspHI	2	3715, 4723	Hsp92I	4	83, 109, 1502,
BspMI	1	1474	-		4425
BsrGI	1	566	KasI	1	108

**Note:** The enzymes listed in boldface type are available from Promega.



#### VIII.A. pGL2-Basic Vector Restriction Sites (continued)

Table 3. Restriction Enzymes That Cut the pGL2-Basic Vector 1–5 Times (continued).

Enzyme	# of Sites	Location	Enzyme	# of Sites	Location
KpnI	1	12	SacI	1	18
MluI	1	22	SalI	1	2745
MspA1I	5	139, 1429, 3337,	ScaI	1	4368
		3582, 4523	SgrAI	1	1504
NaeI	2	2865, 4934	SinI	3	1255, 4026, 4248
NarI	1	109	SmaI	1	3
NgoMIV	2	2863, 4932	SphI	1	739
NheI	1	28	SplI	1	230
NspI	2	739, 2999	SspI	5	2323, 2476, 4692,
PacI	1	1400			5245, 5360
PaeR7I	1	33	StyI	1	2192
PflMI	1	2044	VspI	2	2411, 4060
PpuMI	1	1255	XbaI	1	123
PshAI	1	2810	XcmI	1	811
Psp5II	1	1255	XhoI	1	33
PspAI	1	1	XmaI	1	1
PvuI	2	4258, 5304	XmnI	1	4487

Table 4. Restriction Enzymes That Do Not Cut the pGL2-Basic Vector.

AatII	Bpu1102I	Eco52I	PmeI	SpeI
AflII	Bsp120I	Eco72I	PmlI	SrfI
AgeI	BssHII	FseI	Ppu10I	Sse8387I
ApaI	Bst1107I	I-PpoI	PstI	StuI
AscI	Bst98I	NcoI	PvuII	SwaI
AvrII	BstXI	NdeI	RsrII	Tth111I
BalI	BstZI	NotI	SacII	
BbrPI	CspI	NruI	SfiI	
BclI	DsaI	NsiI	SgfI	
BlpI	EagI	PinAI	SnaBI	

Note: The enzymes listed in boldface type are available from Promega.



Table 5. Restriction Enzymes That Cut the pGL2-Basic Vector Six or More Times.

AciI	Bst71I	HaeIII	MboII	Sau96I
AluI	BstOI	HgaI	MnlI	ScrFI
BanI	BstUI	HhaI	MseI	SfaNI
BbvI	CfoI	HinfI	MspI	TaqI
BsaOI	DdeI	HpaII	NciI	TfiI
BsaJI	DpnI	HphI	NdeII	Tru9I
BsaMI	DpnII	Hsp92II	NlaIII	XhoII
BsmI	DraI	MaeI	NlaIV	
Bsp1286I	EarI	MaeII	PleI	
BsrI	Fnu4HI	MaeIII	RsaI	
BsrSI	FokI	MboI	Sau3AI	

#### VIII.B. pGL2-Promoter Vector Restriction Sites

The following restriction enzyme tables were constructed using DNASTAR® sequence analysis software. Please note that we have not verified this information by restriction digestion with each enzyme listed. The location given specifies the 3′ end of the cut DNA (the base to the left of the cut site). For more information on the cut sites of these enzymes, or if you identify a discrepancy, please contact your local Promega Branch or Distributor. In the U.S., contact Promega Technical Services at 800-356-9526. The pGL2-Promoter Vector sequence is also available in the GenBank® database (GenBank®/EMBL Accession Number X65326) and online at: www.promega.com/vectors/

Table 6. Restriction Enzymes That Cut the pGL2-Promoter Vector 1-5 Times.

Enzyme	# of Sites	Location	Enzyme	# of Sites	Location
AccB7I	1	2236	BbsI	5	278, 1556, 1672,
AccI	1	2938			2384, 3016
AccIII	2	963, 1479	BbuI	1	931
Acc65I	1	8	BglI	3	176, 4200, 5468
AcyI	4	275, 301, 1694,	BglII	1	37
·		4617	BsaI	1	4141
AflIII	3	22, 761, 3187	BsaAI	3	422, 5229, 5562
Alw26I	4	1291, 1523, 4141,	BsaBI	2	42, 2699
		4917	BsaHI	4	275, 301, 1694,
Alw44I	2	3501, 4747			4617
AlwNI	1	3603	BspHI	2	3907, 4915
AspHI	5	18, 1733, 3505,	BspMI	1	1666
•		4666, 4751	BsrGI	1	758
AvaI	3	1, 33, 1324	BssSI	2	3360, 4744
AvaII	3	1447, 4218, 4440	BstEII	1	875
AvrII	1	223	Bsu36I	1	881
BamHI	1	2931	Cfr10I	5	537, 1696, 3055,
BanII	3	18, 1292, 5158			4160, 5124
BbeI	1	304	ClaI	1	1633



#### VIII.B. pGL2-Promoter Vector Restriction Sites (continued)

Table 6. Restriction Enzymes That Cut the pGL2-Promoter Vector 1-5 Times (continued).

Enzyme	# of Sites	Location	Enzyme	# of Sites	Location
Csp45I	2	437, 1225	NcoI	1	130
DraII	1	1447	NgoMIV	2	3055, 5124
DraIII	1	5232	NheI	1	28
DrdI	2	3295, 5276	NspI	2	931, 3191
DsaI	1	130	PacI	1	1592
EaeI	1	4468	PaeR7I	1	33
EclHKI	1	4080	PflMI	1	2236
Eco47III	1	3063	PpuMI	1	1447
Eco81I	1	881	PshAI	1	3002
EcoICRI	1	16	Psp5II	1	1447
EcoNI	1	1885	PspAI	1	1
EcoRI	1	855	PvuI	2	4450, 5496
<b>EcoRV</b>	1	1606	SacI	1	18
EheI	1	302	SalI	1	2937
FspI	2	4302, 5475	ScaI	1	4560
HaeII	5	304, 3065, 3435,	SfiI	1	176
		5074, 5082	SgrAI	1	1696
HincII	4	1572, 2800, 2939,	SinI	3	1447, 4218, 4440
		5643	SmaI	1	3
HindII	4	1572, 2800, 2939,	SphI	1	931
		5643	SplI	1	422
HindIII	1	239	SspI	5	2515, 2668, 4884,
HpaI	2	2800, 5643	_		5437, 5552
Hsp92I	4	275, 301, 1694,	StuI	1	222
		4617	StyI	3	130, 223, 2384
KasI	1	300	VspI	2	2603, 4252
KpnI	1	12	XbaI	1	315
MluI	1	22	XcmI	1	1003
MspA1I	5	331, 1621, 3529,	XhoI	1	33
-		3774, 4715	XmaI	1	1
NaeI	2	3057, 5126	XmnI	1	4679
NarI	1	301			



Table 7. Restriction Enzymes That Do Not Cut the pGL2-Promoter Vector.

AatII	Bpu1102I	Eco52I	PmeI	SpeI
AflII	Bsp120I	Eco72I	PmlI	SrfI
AgeI	BssHII	FseI	Ppu10I	Sse8387I
ApaI	Bst1107I	I-PpoI	PstI	SwaI
AscI	Bst98I	NdeI	PvuII	Tth111I
BalI	BstXI	NotI	RsrII	
BbrPI	BstZI	NruI	SacII	
BclI	CspI	NsiI	SgfI	
BlpI	EagI	PinAI	SnaBI	

Table 8. Restriction Enzymes That Cut the pGL2-Promoter Vector More Than Six Times.

AciI	Bst71I	HaeIII	MboII	Sau96I
AluI	BstOI	HgaI	MnlI	ScrFI
BanI	BstUI	HhaI	MseI	SfaNI
BbvI	CfoI	HinfI	MspI	TaqI
BsaOI	DdeI	HpaII	NciI	TfiI
BsaJI	DpnI	HphI	NdeII	Tru9I
BsaMI	DpnII	Hsp92II	NlaIII	XhoII
BsmI	DraI	MaeI	NlaIV	
Bsp1286I	EarI	MaeII	PleI	
BsrI	Fnu4HI	MaeIII	RsaI	
BsrSI	FokI	MboI	Sau3AI	

Note: The enzymes listed in boldface type are available from Promega.



#### VIII.C. pGL2-Enhancer Vector Restriction Sites

The following restriction enzyme tables were constructed using DNASTAR® sequence analysis software. Please note that we have not verified this information by restriction digestion with each enzyme listed. The location given specifies the 3′ end of the cut DNA (the base to the left of the cut site). For more information on the cut sites of these enzymes, or if you identify a discrepancy, please contact your local Promega Branch or Distributor. In the U.S., contact Promega Technical Services at 800-356-9526. The pGL2-Enhancer Vector sequence is also available in the GenBank® database (GenBank®/EMBL Accession Number X65325) and online at: www.promega.com/vectors/

Table 9. Restriction Enzymes That Cut the pGL2-Enhancer Vector 1-5 Times.

Enzyme	# of Sites	Location	Enzyme	# of Sites	Location
AccB7I	1	2044	Cfr10I	5	345, 1504, 3120,
AccI	1	3003			4225, 5189
AccIII	2	771, 1287	ClaI	1	1441
Acc65I	1	8	Csp45I	2	245, 1033
AcyI	4	83,109,1502, 4682	DraII	1	1255
AflIII	3	22, 569, 3252	DraIII	1	5297
Alw26I	4	1099, 1331, 4206,	DrdI	2	3360, 5341
		4982	DsaI	1	2748
Alw44I	2	3566, 4812	EaeI	1	4533
AlwNI	1	3668	<b>EclHKI</b>	1	4145
AspHI	5	18, 1541, 3570,	Eco47III	1	3128
		4731, 4816	Eco81I	1	689
AvaI	3	1, 33, 1132	<b>EcoICRI</b>	1	16
AvaII	3	1255, 4283, 4505	EcoNI	1	1693
BamHI	1	2996	EcoRI	1	663
BanII	3	18, 1100, 5223	<b>EcoRV</b>	1	1414
BbeI	1	112	EheI	1	110
BbsI	5	86, 1364, 1480,	FspI	2	4367, 5540
		2192, 3081	HaeII	5	112, 3130, 3500,
BbuI	3	739, 2843, 2915			5139, 5147
BglI	2	4265, 5533	HincII	4	1380, 2608, 3004,
BglII	1	37			5708
BsaI	1	4206	HindII	4	1380, 2608, 3004,
BsaAI	3	230, 5294, 5627			5708
BsaBI	1	2507	HindIII	1	47
BsaHI	4	83, 109,1502,	HpaI	2	2608, 5708
		4682	Hsp92I	4	83, 109, 1502,
BspHI	2	3972, 4980	1		4682
BspMI	1	1474	KasI	1	108
BsrGI	1	566	KpnI	1	12
BssSI	2	3425, 4809	MluI	1	22
BstEII	1	683	MspA1I	5	139, 1429, 3594,
Bsu36I	1	689			3839, 4780



Table 9. Restriction Enzymes That Cut the pGL2-Enhancer Vector 1-5 Times (continued).

Enzyme	# of Sites	Location	Enzyme	# of Sites	Location
NaeI	2	3122, 5191	SacI	1	18
NarI	1	109	SalI	1	3002
NcoI	1	2748	ScaI	1	4625
NgoMIV	2	3120, 5189	SgrAI	1	1504
NheI	1	28	SinI	3	1255, 4283, 4505
NsiI	2	2841, 2913	SmaI	1	3
NspI	4	739, 2843, 2915,	SphI	3	739, 2843, 2915
-		3256	SplI	1	230
PacI	1	1400	SspI	5	2323, 2476, 4949
PaeR7I	1	33	_		5502, 5617
PflMI	1	2044	StyI	2	2192, 2748
Ppu10I	2	2837, 2909	VspI	2	2411, 4317
PpuMI	1	1255	XbaI	1	123
PshAI	1	3067	XcmI	1	811
Psp5II	1	1255	XhoI	1	33
PspAI	1	1	XmaI	1	1
PvuI	2	4515, 5561	XmnI	1	4744

Table 10. Restriction Enzymes That Do Not Cut the pGL2-Enhancer Vector.

AatII	BlpI	EagI	PmeI	SpeI
AflII	Bpu1102I	Eco52I	PmlI	SrfI
AgeI	Bsp120I	Eco72I	PstI	Sse8387I
ApaI	BssHII	FseI	PvuII	StuI
AscI	Bst1107I	I-PpoI	RsrII	SwaI
AvrII	Bst98I	NdeI	SacII	Tth111I
BalI	BstXI	NotI	SfiI	
BbrPI	BstZI	NruI	SgfI	
BclI	CspI	PinAI	SnaBI	

Table 11. Restriction Enzymes That Cut the pGL2-Enhancer Vector More Than Six Times.

AciI	BsrSI	Fnu4HI	MaeII	PleI
AluI	Bst71I	FokI	MaeIII	RsaI
BanI	BstOI	HaeIII	MboI	Sau3AI
BbvI	BstUI	HgaI	MboII	Sau96I
BsaOI	CfoI	HhaI	MnlI	ScrFI
BsaJI	DdeI	HinfI	MseI	SfaNI
BsaMI	DpnI	HpaII	MspI	TaqI
BsmI	DpnII	HphI	NciI	TfiI
Bsp1286I	DraI	Hsp92II	NdeII	Tru9I
BsrI	EarI	MaeI	NlaIII	XhoII

**Note:** The enzymes listed in boldface type are available from Promega.

 Promega
 Corporation
 • 2800
 Woods
 Hollow
 Road
 • Madison,
 WI
 53711-5399
 USA

 Toll
 Free
 in
 USA
 800-356-9526
 • Phone
 608-274-4330
 • Fax
 608-277-2516
 • www.promega.com

 Printed in USA.
 Page 19

 Revised 3/07
 Page 19



#### VIII.D. pGL2-Control Vector Restriction Sites

The following restriction enzyme tables were constructed using DNASTAR® sequence analysis software. Please note that we have not verified this information by restriction digestion with each enzyme listed. The location given specifies the 3′ end of the cut DNA (the base to the left of the cut site). For more information on the cut sites of these enzymes, or if you identify a discrepancy, please contact your local Promega Branch or Distributor. In the U.S., contact Promega Technical Services at 800-356-9526. The pGL2-Control Vector sequence is also available in the GenBank® database (GenBank®/EMBL Accession Number X65324) and online at: www.promega.com/vectors/

Table 12. Restriction Enzymes That Cut the pGL2-Control Vector 1-5 Times.

Enzyme	# of Sites	Location	Enzyme	# of Sites	Location
AccB7I	1	2236	BstEII	1	875
AccI	1	3195	Bsu36I	1	881
AccIII	2	963, 1479	Cfr10I	5	537, 1696, 3312,
Acc65I	1	8			4417, 5381
AcyI	4	275, 301, 1694,	ClaI	1	1633
		4874	Csp45I	2	437, 1225
AflIII	3	22, 761, 3444	DraII	1	1447
Alw26I	4	1291, 1523, 4398	DraIII	1	5489
		5174	DrdI	2	3552, 5533
Alw44I	2	3758, 5004	DsaI	2	130, 2940
AlwNI	1	3860	EaeI	1	4725
AspHI	5	18, 1733, 3762,	<b>EclHKI</b>	1	4337
•		4923, 5008	Eco47III	1	3320
AvaI	3	1, 33, 1324	Eco81I	1	881
AvaII	3	1447, 4475, 4697	<b>EcoICRI</b>	1	16
AvrII	1	223	EcoNI	1	1885
BamHI	1	3188	EcoRI	1	855
BanII	3	18, 1292, 5415	<b>EcoRV</b>	1	1606
BbeI	1	304	EheI	1	302
BbsI	5	278, 1556, 1672,	HaeII	5	304, 3322, 3692,
		2384, 3273			5331, 5339
BbuI	3	931, 3035, 3107	HincII	4	1572, 2800, 3196,
BglI	3	176, 4457, 5725			5900
BglII	1	37	HindII	4	1572, 2800, 3196,
BsaI	1	4398			5900
BsaAI	3	422, 5486, 5819	HindIII	1	239
BsaBI	2	42, 2699	HpaI	2	2800, 5900
BsaHI	4	275, 301, 1694,	Hsp92I	4	275, 301, 1694,
		4874	-		4874
BspHI	2	4164, 5172	KasI	1	300
BspMI	1	1666	KpnI	1	12
BsrGI	1	758	MluI	1	22
BssSI	2	3617, 5001			



Table 12. Restriction Enzymes That Cut the pGL2-Control Vector 1–5 Times (continued).

Enzyme	# of Sites	Location	Enzyme	# of Sites	Location
MspA1I	5	331, 1621, 3786,	SalI	1	3194
		4031, 4972	ScaI	1	4817
NaeI	2	3314, 5383	SfiI	1	176
NarI	1	301	SgrAI	1	1696
NcoI	2	130, 2940	SinI	3	1447, 4475, 4697
NgoMIV	2	3312, 5381	SmaI	1	3
NheI	1	28	SphI	3	931, 3035, 3107
NsiI	2	3033, 3105	SplI	1	422
NspI	4	931, 3035, 3107,	SspI	5	2515, 2668, 5141,
		3448			5694, 5809
PacI	1	1592	StuI	1	222
PaeR7I	1	33	StyI	4	130, 223, 2384,
PflMI	1	2236			2940
Ppu10I	2	3029, 3101	VspI	2	2603, 4509
PpuMI	1	1447	XbaI	1	315
PshAI	1	3259	XcmI	1	1003
Psp5II	1	1447	XhoI	1	33
PspAI	1	1	XmaI	1	1
PvuI	2	4707, 5753	XmnI	1	4936
SacI	1	18			

Table 13. Restriction Enzymes That Do Not Cut the pGL2-Control Vector.

AatII	BlpI	CspI	NruI	SgfI
AflII	Bpu1102I	EagI	PinAI	SnaBI
AgeI	Bsp120I	Eco52I	PmeI	SpeI
ApaI	BssHII	Eco72I	PmlI	SrfI
AscI	Bst1107I	FseI	PstI	Sse8387I
BalI	Bst98I	I-PpoI	PvuII	SwaI
BbrPI	BstXI	NdeI	RsrII	Tth111I
BclI	BstZI	NotI	SacII	

**Note:** The enzymes listed in boldface type are available from Promega.



#### VIII.D. pGL2-Control Vector Restriction Sites (continued)

Table 14. Restriction Enzymes That Cut the pGL2-Control Vector More Than Six Times.

AciI	Bst71I	HaeIII	MboII	Sau96I
AluI	BstOI	HgaI	MnlI	ScrFI
BanI	BstUI	HhaI	MseI	SfaNI
BbvI	CfoI	HinfI	MspI	TaqI
BsaOI	DdeI	HpaII	NciI	TfiI
BsaJI	DpnI	HphI	NdeII	Tru9I
BsaMI	DpnII	Hsp92II	NlaIII	XhoII
BsmI	DraI	MaeI	NlaIV	
Bsp1286I	EarI	MaeII	PleI	
BsrI	Fnu4HI	MaeIII	RsaI	
BsrSI	F <b>okI</b>	MboI	Sau3AI	

Note: The enzymes listed in boldface type are available from Promega.

#### VIII.E. References

- Groskreutz, D. et al. (1995) Increased expression and convenience with the new pGL3 Luciferase Reporter Vectors. Promega Notes 50, 2–8.
- Sambrook, J. et al. (1989) Molecular Cloning, A Laboratory Manual, Cold Spring Harbor Press, Cold Spring Harbor, NY.
- Henikoff, S. (1987) Unidirectional digestion with exonuclease III in DNA sequence analysis. Methods Enzymol. 155, 156-65.
- Schenborn, E. et al. (1995) Tfx™ Reagent: A new transfection reagent for eukaryotic cells. Promega Notes 52, 2-7.
- Schenborn, E. and Goiffon, V. (1991) Optimization of Transfectam®-mediated transfection using a luciferase reporter system. *Promega Notes* 33, 8–11.
- Cullen, B. (1987) Use of eukaryotic expression technology in functional analysis of cloned genes. Methods Enzymol. 152, 684–704.
- Ausubel, F.M. et al. (1988) Current Protocols in Molecular Biology, John Wiley and Sons, NY.
- Rosenthal, N. (1987) Identification of regulatory elements in cloned genes with functional assays. Methods Enzymol. 152, 704–20.
- Hawkins, E., Butler, B. and Wood, K.V. (2000) Bright-Glo™ and Steady-Glo™ Luciferase Assay Systems: Reagents for academic and industrial applications. Promega Notes 75, 3–6.



#### VIII.F. Related Products

Product	Size	Cat.#
GLprimer2 (counter clockwise)	2μg	E1661
RVprimer3 (clockwise)	2μg	E4481
RVprimer4 (counter clockwise)	2μg	E4491
PureYield™ Plasmid Midiprep System	25 preps	A2492
	100 preps	A2495

#### Luciferase Assay Systems

Product	Size	Cat.#
Luciferase Assay System	100 assays	E1500
Bright-Glo™ Luciferase Assay System	10ml	E2610
Steady-Glo® Luciferase Assay System	10ml	E2510
Dual-Luciferase® Reporter Assay System	100 assays	E1910
Dual-Glo™ Luciferase Assay System	10ml	E2920
A : 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1		

Available in additional sizes.

#### pGL4 Luciferase Vectors

Product	Size	Cat.#
pGL4.10[luc2] Vector	20μg	E6651
pGL4.11[luc2P] Vector	20μg	E6661
pGL4.12[luc2CP] Vector	20μg	E6671
pGL4.13[luc2/SV40] Vector	20μg	E6681
pGL4.14[luc2/Hygro] Vector	20μg	E6691
pGL4.17[luc2/Neo] Vector	20μg	E6721
pGL4.20[luc2/Puro] Vector	20μg	E6751
pGL4.23[luc2/minP] Vector	20μg	E8411
pGL4.26[luc2/minP/Hygro] Vector	20μg	E8441
pGL4.29[luc2P/CRE/Hygro] Vector	20μg	E8471
pGL4.30[luc2P/NFAT-RE/Hygro] Vector	20μg	E8481
pGL4.31[luc2P/Gal4UAS/Hygro] Vector	20μg	C9351

The complete listing of pGL4 Luciferase Vectors can be found at: www.promega.com/pgl4/



#### VIII.F. Related Products (continued)

#### Luminometers

Product	Size	Cat.#
GloMax <sup>TM</sup> 20/20 Luminometer	1 instrument	E5311
GloMax <sup>TM</sup> 20/20 Luminometer with Single Auto-Injector	1 instrument	E5321
GloMax <sup>TM</sup> 20/20 Luminometer with Dual Auto-Injector	1 instrument	E5331
GloMax <sup>TM</sup> 96 Microplate Luminometer	1 each	E6501
GloMax™ 96 Microplate Luminometer		
with Single Reagent Injector	1 each	E6511
GloMax™ 96 Microplate Luminometer		
with Dual Reagent Injectors	1 each	E6521

(e)The method of recombinant expression of Coleoptera luciferase is covered by U.S. Pat. Nos. 5,583,024, 5,674,713 and 5,700,673.

© 1992-2007 Promega Corporation. All Rights Reserved.

Dual-Luciferase, ProFection, Steady-Glo and Transfectam are registered trademarks of Promega Corporatio. Bright-Glo, Dual-Glo, GloMax, PureYield and Tfx are trademarks of Promega Corporation.

DNASTAR is a registered trademark of DNASTAR, Inc. GenBank is a registered trademark of the U.S. Dept. of Health and Human Services.

Products may be covered by pending or issued patents or may have certain limitations. Please visit our Web site for more information.

All prices and specifications are subject to change without prior notice.

Product claims are subject to change. Please contact Promega Technical Services or access the Promega online catalog for the most up-to-date information on Promega products.